Farxiga Approved in the United States to Treat Heart Failure
On Monday, October 21, 2019, the U.S. Food and Drug Administration (FDA) approved AstraZeneca's diabetes drug, Farxiga, for use in the U.S. to treat and reduce the risks of hospitalization from heart failure in adults with Type 2 diabetes and other cardiovascular risks.
Abbott and Omada Health Partner to Help People With Type 2 Diabetes
On October 14, 2019, Abbott and Omada Health announced a partnership to integrate Abbott's FreeStyle Libre continuous glucose monitoring system (CGM) with Omada Health's digital program for people with Type 2 diabetes.
ADA 2019 – American Diabetes Association’s 79th Annual Conference
The Beyond Type 2 team's live coverage of the American Diabetes Association's 79th Annual Conference.
FDA Approves Invokana to Treat Diabetic Kidney Disease
On Monday, September 30, 2019, the U.S. Food and Drug Administration (FDA) approved a new indication for the Janssen Pharmaceutical Companies of Johnson & Johnson's INVOKANA (canagliflozin) to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure in patients with Type 2 diabetes and diabetic nephropathy.
FDA Approves First Oral Semaglutide Rybelsus from Novo Nordisk
On September 20, the FDA approved the first oral GLP-1 Rybelsus (semaglutide). Manufactured by Novo Nordisk, the GLP-1 drug showed impressive efficacy in the PIONEER Trial results presented at EASD 2019.
Study Shows Combination Therapy Leads to Better Outcomes for Newly Diagnosed T2D Patients
The new study shows combination therapy in patients newly diagnosed with Type 2 diabetes provides better outcomes than metformin alone.
FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke
On September 10 the FDA approved the Gvoke HypoPen and Gvoke PFS, emergency glucagon rescue devices for the treatment of severe hypoglycemia.
Half-Price Generics of NovoLog and NovoLog Mix Announced by Novo Nordisk
Novo Nordisk announced that authorized generic versions of NovoLog and NovoLog Mix will be made available on January 2, 2020.
Nasal Glucagon Baqsimi Approved by the FDA
On Thursday, the Food and Drug Administration approved Eli Lilly and Company's Baqsimi, a non-injectable, nasal glucagon and the first of its kind.
